Platinum kinetics in patients treated with cis-Dichlorodiammine platinum (II)

R. G. Buice, M. S. Soloway

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The pharmacokinetics of platinum have been studied in six patients following treatment with cis-dichlorodiammine platinum (CDDP) for metastatic bladder cancer. Each patient received CDDP by 15 min intravenous infusion with total doses ranging from 90 to 120 mg (360 to 480 mg/h). Platinum disposition was biexponential with a relatively rapid distribution and slow elimination. Individual patient elimination half-lives varied from 16.1 to 53.3 h. Although normalized for body weight, individual distribution parameters, V1 and V(area), varied from 0.17 to 0.70 L/kg and 0.67 to 1.47 L/kg, respectively. Total body clearance (TBC) also revealed considerable interpatient differences (7 to 40 ml/kg/h). Observed parameter variations could not be explained in terms of existing clinical data. These findings suggest that the pharmacokinetics of platinum in the individual patient might be difficult to predict, and thus serum platinum concentrations should be monitored during cis-dichlorodiammine platinum (II) therapy.

Original languageEnglish
Pages (from-to)293-296
Number of pages4
JournalTherapeutic Drug Monitoring
Volume4
Issue number3
StatePublished - Jan 1 1982
Externally publishedYes

Fingerprint

Platinum
Cisplatin
Kinetics
Pharmacokinetics
Patient treatment
Intravenous Infusions
Urinary Bladder Neoplasms
Body Weight
Therapeutics
Serum

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Health, Toxicology and Mutagenesis
  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health
  • Pharmacology
  • Toxicology

Cite this

Platinum kinetics in patients treated with cis-Dichlorodiammine platinum (II). / Buice, R. G.; Soloway, M. S.

In: Therapeutic Drug Monitoring, Vol. 4, No. 3, 01.01.1982, p. 293-296.

Research output: Contribution to journalArticle

Buice, R. G. ; Soloway, M. S. / Platinum kinetics in patients treated with cis-Dichlorodiammine platinum (II). In: Therapeutic Drug Monitoring. 1982 ; Vol. 4, No. 3. pp. 293-296.
@article{c58f168036c64575ae4413b2a37fd567,
title = "Platinum kinetics in patients treated with cis-Dichlorodiammine platinum (II)",
abstract = "The pharmacokinetics of platinum have been studied in six patients following treatment with cis-dichlorodiammine platinum (CDDP) for metastatic bladder cancer. Each patient received CDDP by 15 min intravenous infusion with total doses ranging from 90 to 120 mg (360 to 480 mg/h). Platinum disposition was biexponential with a relatively rapid distribution and slow elimination. Individual patient elimination half-lives varied from 16.1 to 53.3 h. Although normalized for body weight, individual distribution parameters, V1 and V(area), varied from 0.17 to 0.70 L/kg and 0.67 to 1.47 L/kg, respectively. Total body clearance (TBC) also revealed considerable interpatient differences (7 to 40 ml/kg/h). Observed parameter variations could not be explained in terms of existing clinical data. These findings suggest that the pharmacokinetics of platinum in the individual patient might be difficult to predict, and thus serum platinum concentrations should be monitored during cis-dichlorodiammine platinum (II) therapy.",
author = "Buice, {R. G.} and Soloway, {M. S.}",
year = "1982",
month = "1",
day = "1",
language = "English",
volume = "4",
pages = "293--296",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Platinum kinetics in patients treated with cis-Dichlorodiammine platinum (II)

AU - Buice, R. G.

AU - Soloway, M. S.

PY - 1982/1/1

Y1 - 1982/1/1

N2 - The pharmacokinetics of platinum have been studied in six patients following treatment with cis-dichlorodiammine platinum (CDDP) for metastatic bladder cancer. Each patient received CDDP by 15 min intravenous infusion with total doses ranging from 90 to 120 mg (360 to 480 mg/h). Platinum disposition was biexponential with a relatively rapid distribution and slow elimination. Individual patient elimination half-lives varied from 16.1 to 53.3 h. Although normalized for body weight, individual distribution parameters, V1 and V(area), varied from 0.17 to 0.70 L/kg and 0.67 to 1.47 L/kg, respectively. Total body clearance (TBC) also revealed considerable interpatient differences (7 to 40 ml/kg/h). Observed parameter variations could not be explained in terms of existing clinical data. These findings suggest that the pharmacokinetics of platinum in the individual patient might be difficult to predict, and thus serum platinum concentrations should be monitored during cis-dichlorodiammine platinum (II) therapy.

AB - The pharmacokinetics of platinum have been studied in six patients following treatment with cis-dichlorodiammine platinum (CDDP) for metastatic bladder cancer. Each patient received CDDP by 15 min intravenous infusion with total doses ranging from 90 to 120 mg (360 to 480 mg/h). Platinum disposition was biexponential with a relatively rapid distribution and slow elimination. Individual patient elimination half-lives varied from 16.1 to 53.3 h. Although normalized for body weight, individual distribution parameters, V1 and V(area), varied from 0.17 to 0.70 L/kg and 0.67 to 1.47 L/kg, respectively. Total body clearance (TBC) also revealed considerable interpatient differences (7 to 40 ml/kg/h). Observed parameter variations could not be explained in terms of existing clinical data. These findings suggest that the pharmacokinetics of platinum in the individual patient might be difficult to predict, and thus serum platinum concentrations should be monitored during cis-dichlorodiammine platinum (II) therapy.

UR - http://www.scopus.com/inward/record.url?scp=0019984653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019984653&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 293

EP - 296

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 3

ER -